Article Details

Alterity Therapeutics Announces Expanded ATH434 Phase 2 Clinical Development Program

Retrieved on: 2021-10-20 06:33:09

Tags for this article:

Click the tags to see associated articles and topics

Alterity Therapeutics Announces Expanded ATH434 Phase 2 Clinical Development Program. View article details on hiswai:

Excerpt

19, 2021 /PRNewswire/ -- Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) ("Alterity" or "the Company"), a biotechnology company dedicated to developing ...

Article found on: www.wbko.com

View Original Article

This article is found inside other hiswai user's workspaces. To start your own collection, sign up for free.

Sign Up